학술논문
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
Document Type
Artikel
Author
Source
Applied health economics and health policy. 18(1):5-16
Subject
Language
English
English
English
ISSN
1179-1896